Recombinant Human LILRB5/CD85c/LIR-8 Protein, CF Summary
Arg18-His456, with a C-terminal 6-His tag
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
|Formulation||Lyophilized from a 0.2 μm filtered solution in PBS.|
|Reconstitution||Reconstitute at 100 μg/mL in PBS.|
|Shipping||The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.|
|Stability & Storage:||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
LIR8, also known as CD85c and LILRB5, belongs to the Leukocyte immunoglobulin-like receptors (LILR) family of transmembrane glycoproteins involved in regulating immune responses (1,2). There are at least thirteen LILR family members and are divided into activating (LILRA) or inhibiting (LILRB) molecules (1,2). Mature human LIR8 consists of an extracellular domain (ECD) with four Ig-like domains, a transmembrane segment, and a cytoplasmic domain with two immunoreceptor tyrosine-based inhibitory motifs (ITIM). Alternative splicing of human LIR8 generates at least 2 isoforms, one lacking the second Ig-like domain. The LILR family appears to be primate-specific receptors in terms of sequence homology. LIR8 is expressed on NK cells and in the tryptic granules of mast cells and negatively regulates immune cell activation (3, 4). It is present on the mast cell surface following cell activation and degranulation (4). Activated mast cells may also release soluble forms of LIR8 (3). LIR8 has also been shown to be expressed on T cells and induce CD8+ T cell proliferation (5). Consistent with the demonstrated binding of LILRB2 to Angiopoietin-like 2 and 5 (6), R&D Systems in-house testing indicates that LIR8 binds to Angiopoietin-like 7. Recently, a common missense variant of LIR8 was found to be associated with statin intolerance and myalgia (7).
- Brown, D. et al. (2004) Tissue antigens. 64:215.
- Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
- Borges, L. et al. (1997) J. Immunol. 159:5192.
- Tedla, N. et al. (2008) J. Leukoc. Biol. 83:334.
- Hogan, H. E. et al. (2016) Sci Rep. 6:21780.
- Zheng, J. et al. (2012) Nature 485:656.
- Siddigui, M. et al. (2017) Eur. Heart J. 38:3569.
No product specific FAQs exist for this product, however you mayView all Proteins and Enzyme FAQs
Reviews for Recombinant Human LILRB5/CD85c/LIR-8 Protein, CF
There are currently no reviews for this product. Be the first to review Recombinant Human LILRB5/CD85c/LIR-8 Protein, CF and earn rewards!
Have you used Recombinant Human LILRB5/CD85c/LIR-8 Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image